Pfizer v. Pfizer: Sutent Indication Expansion Will Hinge On Conflicting Trials
US FDA's Oncologic Drugs Advisory Committee will consider whether positive S-TRAC or negative ASSURE data should guide decision on expanding Sutent's renal cell carcinoma indication.
